Sector revisions Vertex Pharmaceuticals Incorporated

Stocks

Market Closed - Nasdaq 16:00:00 2026-08-27 EDT			5-day change	1st Jan Change
547.55 ^USD	+0.05%		+1.35%	+20.78%

08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	VERTEX PHARMACEUTICALS INCORPORATED							25
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							22
	ABBVIE INC.							29
	ROCHE HOLDING AG							18
	NOVARTIS AG							21
	ASTRAZENECA PLC							22
	AMGEN INC.							29
	NOVO NORDISK A/S							23
	GILEAD SCIENCES, INC.							27
	PFIZER INC.							26
	BRISTOL-MYERS SQUIBB COMPANY							24
	SANOFI							23
	GSK PLC							20
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							16
	BAYER AG							18
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	TEVA PHARMACEUTICAL INDUSTRIES LIMITED							10
	HALEON PLC							17
	Average							22
	Weighted average by Cap.							24